Handbook of Hematologic Malignancies 3rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options. This edition introduces a completely new set of challenging clinical cases, designed to rigorously test clinicians' knowledge of pathologic diagnosis and clinical presentation. With over 35 new FDA-approved indications since the second edition-featuring groundbreaking advancements such as CAR-T therapy-this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers. Key Features: New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance. Entirely new unfolding clinical cases with board-style questions, enhancing critical thinking and knowledge application with every clinical chapter. Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading. Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas. Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.
David A. Sallman, MD, Associate Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida Morsani College of Medicine, Tampa, Florida Ateefa Chaudhury, MD, Hematologist, New Mexico Cancer Center, Albuquerque, New Mexico Hayder Saeed, MD, Associate member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida Ling Zhang, MD, Senior Member, Professor, Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Contributors Preface Abbreviations PART I. INTRODUCTION AND OVERVIEW 1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses 2. ICC and WHO Classifications and Potential Future Harmonization 3. Familial/Inherited Variants and Risks of Hematologic Malignancies 4. Diagnostic Approaches to Hematologic Malignancies 5. Minimal Residual Disease Assays 6. Personalized Approach to Hematologic Malignancies PART II. MYELOPROLIFERATIVE NEOPLASMS 7. Polycythemia Vera 8. Essential Thrombocythemia 9. Primary Myelofibrosis 10. Chronic Myelogenous Leukemia 11. Chronic Neutrophilic Leukemia 12. Systemic Mastocytosis 13. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion (MLN-TK) PART III. MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES 14. CHIP, CCUS and Precursor States of Myeloid Neoplasms 15. Myelodysplastic Syndromes 16. Aplastic Anemia 17. Paroxysmal Nocturnal Hemoglobinuria PART IV. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS 18. Myelodysplastic/Myeloproliferative Neoplasms 19. Chronic Myelomonocytic Leukemia PART V. ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES 20. Acute Myeloid Leukemia 21. Secondary AML and AML-MRC 22. Acute Promyelocytic Leukemia 23. Blastic Plasmacytoid Dendritic Cell Neoplasm PART VI. ACUTE LYMPHOID LEUKEMIA 24. B-Lymphoblastic Leukemia/Lymphoma 25. BCR-ABL1+ B-Lymphoblastic Leukemia 26. T-Cell Acute Lymphoblastic Leukemia/Lymphoma PART VII. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE 27. Acute Leukemia of Ambiguous Lineage PART VIII. MATURE T- AND NK-CELL LEUKEMIA 28. T-Cell Prolymphocytic Leukemia 29. T-Cell Large Granular Lymphocytic Leukemia 30. Aggressive Natural Killer Cell Leukemia PART IX. PLASMA CELL DISORDERS 31. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas 32. Multiple Myeloma 33. Waldenstroem Macroglobulinemia 34. Immunoglobulin Light Chain Amyloidosis AL PART X. HODGKIN LYMPHOMA 35. Hodgkin Lymphoma PART XI. NON-HODGKIN LYMPHOMA 36. Diagnosis and Classification of Non-Hodgkin Lymphomas PART XII. MATURE B-CELL LYMPHOMA VERY AGGRESIVE 37. Burkitt Lymphoma AGGRESSIVE 38. Diffuse Large B-Cell Lymphoma 39. Double-Hit Lymphoma 40. Mantle Cell Lymphoma 41. Primary Central Nervous System Lymphoma 42. HIV-Related Lymphomas 43. Follicular Lymphoma 44. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 45. Hairy Cell Leukemia 46. Marginal Zone Lymphoma PART XIII. MATURE T- AND NK-CELL LYMPHOMA 47. Peripheral T-Cell Lyphoma 48. Adult T-Cell Leukemia/Lymphoma 49. Anaplastic Large Cell Lymphoma 50. Extranodal Natural Killer/T-Cell Lymphoma 51. Mycosis Fungoides/Sezary Syndrome 52. Hepatosplenic T-Cell Lymphoma PART XIV. HISTIOCYTIC/DENDRITIC CELL NEOPLASMS 53. Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Histiocytic Sarcoma 54. Hemophagocytic Lymphohistiocytosis PART XV. BONE MARROW TRANSPLANTATION 55. Autologous Hematopoietic Cell Transplantation 56. Allogeneic Hematopoietic Cell Transplantation PART XVI. NEW CELLULAR IMMUNOTHERAPY 57. CAR-T Overview and Novel Cellular Therapeutic Options 58. CD19 CAR T-Cell Therapy 59. BCMA CAR T-Cell Therapy 60. Cytokine Release Syndrome and Other Toxicities Associated With Cellular Therapies PART XVII. EMERGENCIES IN HEMATOLOGY 61. Cancer-Associated Thrombosis in Hematologic Malignancies 62. Tumor Lysis Syndrome 63. Thrombotic Microangiopathy 64. Therapeutic Apheresis Indications Appendix: Pathology Supplement Index
